Tier 2 — strong

Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men

Jun Wakabayashi, Seiichiro Higashi, Masashi Morifuji
Scientific Reports 2026 16(1):27464

Bibliography

PubMed
PMID 42304075
PubMed Central
PMC13534420
Funding
The study was conducted by investigators at Wellness Science Labs, Meiji Holdings Co., Ltd.
Competing interests
Jun Wakabayashi, Seiichiro Higashi and Masashi Morifuji are employees of Meiji Holdings Co., Ltd.

Study snapshot

DesignRandomized two-period crossover comparative pharmacokinetic study.
ModelHealthy adult men.
Sample14 enrolled; one discontinued after the first intervention, with approximately 13 completing both periods for efficacy comparison.
InterventionSingle 250 mg β-NMN dose administered orally and sublingually in crossover periods separated by an 8-day washout.
DurationAcute 60-minute pharmacokinetic sampling after each administration route; 8-day washout between periods.
EndpointsBlood NMN; Nicotinamide; NAD+; 2PY; 4PY; Route-related tolerability

What the study showed, in plain terms

This crossover trial directly compared a single 250 mg NMN dose taken orally versus sublingually in healthy men.

Sublingual dosing produced a larger early 0–60-minute exposure to the terminal metabolites 2PY and 4PY, but NMN, nicotinamide and NAD+ concentrations did not differ significantly between routes. Both routes were well tolerated. The study therefore shows a route-dependent early metabolite pattern, not proven superior systemic NMN or NAD+ bioavailability.

Key findings

  • 2PY and 4PY incremental exposure was higher after sublingual than oral NMN during the first 60 minutes.
  • Blood NMN, NAM and NAD+ did not significantly differ between routes.
  • No adverse events were reported in the PubMed abstract.
  • The metabolic origin of the increased terminal catabolites could not be distinguished.

What this study can and cannot tell us

The study was small, included only men and assessed only the first 60 minutes after a single dose. Higher terminal-catabolite exposure should not be interpreted as evidence of superior clinical efficacy or greater tissue NAD+ delivery. All authors were Meiji Holdings employees.

Citation network

Articles citing this research paper

7 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified